Guiding Your Strategic Approach of Multimodal Imaging to Advance Targeted Drug Development Outcomes
While we are all living in uncertainty, one reaffirmation is, scientific innovations will need collaboration! The PREDiCT: Imaging Modalities for Oncology Drug Development team is committed to serving this community and helping you to overcome social distancing by going digital!
Advances in multimodal imaging and digital pathology now offer invaluable evidence to fast-track the success of clinical oncology drug candidates. At the PREDiCT: Imaging Modalities for Oncology Drug Development Summit we are showcasing the latest strategic insight from industry experts to explore the benefits of strategic applications of multimodal imaging offering an end-to-end perspective to improve your therapeutic success.
- Utilize the latest imaging techniques to clinically validate your biomarker development strategy and improve targeted drug response
- Understand how digital pathology and AI can improve workflow and tumor classification to fast-track candidate selection strategies
- Monitor the microenvironment and tumor response through an array of imaging techniques for end to end insight across molecular imaging, diagnostics and patient
Both our speakers and our team stand behind the original promise of quality content and discussions enabling you to access the latest data from the likes of Genentech, Takeda, Bristol-Myers Squibb, share lessons learned and meet industry peers in this 1 day digital event.
Join us alongside organisations such as National Institute of Health, Novartis, Glaxo Smith Kline, Regeneron and more and utilize industry insight behind the latest imaging modalities to monitor immune responses in a safe and non-invasive manner and advance your multimodal imaging and digital pathology to fast-track oncology drug development!
IHC/ISH and Digital Pathology Diagnostic Group Director
Medical Director, Oncology Imaging
Team Leader, Preclinical Molecular Imaging
Institute of Cancer Research